New pharmaceutical company opens in Canada
Sterinova to specialise in developing and manufacturing sterile ready-to-use injectable products.
Sterinova Inc., a new pharmaceutical company specialized in the development and manufacture of sterile ready-to-use injectable products, has officially opened its plant in Saint-Hyacinthe today. Its products - syringes or premix solutions containers - will meet the specific needs of healthcare professionals. The announcement was made by Jean-Philippe Gentès, president of Sterinova, accompanied by representatives of the financial partners of the company.
The new company, based in Saint-Hyacinthe, in the Montérégie region, is the result of a total investment of approximately $70 million, made by the Fonds de solidarité FTQ, Quebec Manufacturing Fund (QMF), Saint-Hyacinthe Technopole through the Pharmaceutical Development Centre for the construction of the building and the City of Saint-Hyacinthe for guarantee funding, Desjardins, Investissement Québec and Canada Economic Development for Quebec Regions (CED).
“Sterinova is one of the few pharmaceutical companies in the world to be entirely dedicated to the manufacture of ready-to-use injectable products. Its state-of-the-art technology and its production capacity will make Sterinova an important Canadian player on international markets,” declared Jean-Philippe Gentès.
“The Government of Canada supports enterprises that play a fundamental role in economic growth and job creation to improve economic prospects and security of Canadians. As Minister of Innovation, Science and Economic Development and Minister responsible for CED, I aim to help businesses grow, innovate and export, so that they can create quality jobs and wealth for Canadians,” said the Honourable Navdeep Bains.
“The Québec government is proud to invest $2.3 million in this project that is contributing to the Montérégie region’s economic development. The new plant’s operations will bolster manufacturing in Québec’s life sciences sector and its expertise in the production of value-added products. Our government’s investment is contributing to the establishment of state-of-the-art facilities,” Minister of Economy, Science and Innovation and Minister responsible for the Digital Strategy Dominique Anglade noted.
For Gaétan Morin, President and CEO of the Fonds de solidarité FTQ: “Since 1989, we invested $1.2 billion in Quebec’s life sciences industry. This long experience and a specialized team of 8 people allow the Fund to support dynamic entrepreneurs who invest and above who invest in their business. Jean-Philippe Gentès and Bertrand Bolduc, the founders of Sterinova, are the proof of that. We were the at the launch with Léon Gosselin and the Jafaco group, and we are still here with a total investment of $9 million in venture capital.”
Jean Rochette, for the Quebec Manufacturing Fund: “With this $7 million investment in venture capital, the Quebec Manufacturing Fund wants to support Sterinova in achieving its full potential for growth and value creation. We plan to leverage our expertise in manufacturing and business development to support the company in optimizing its operations.”
Located in the City of Biotechnology in Saint-Hyacinthe, one of the most important economic centers in Quebec and Eastern Canada, Sterinova is a site approved by Health Canada since 2015 for the manufacture of sterile biological products. The building of 6,225 m2 (67,000 square feet) was planned to allow to double its size. The plant is equipped with fully automated equipment and the whole production process meets the Canadian Good Manufacturing Practices (cGMP) and they have an objective to meets the European and American requirements.
“Sterinova’s establishment in Saint-Hyacinthe promises worthwhile economic spinoff for the Montérégie region but also from the standpoint of enhancing the region’s influence as a recognized hub for expertise in the pharmaceutical sector. It is also a major asset for the Cité de la biotechnologie, which can rely on a key stakeholder in the life sciences sector to broaden its visibility and consolidate its operations,” Minister for Rehabilitation, Youth Protection, Public Health and Healthy Living and Minister responsible for the Montérégie region Lucie Charlebois said.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance